Are blood-based protein biomarkers for Alzheimer's disease also involved in other brain disorders? A systematic review.

BACKGROUND Alzheimer's disease (AD) biomarkers are urgently needed for both early and accurate diagnosis and prediction of disease progression. Past research has studied blood-based proteins as potential AD biomarkers, revealing many candidate proteins. To date only limited effort has been made to investigate the disease specificity of AD candidate proteins and whether these proteins are also involved in other neurodegenerative or psychiatric conditions. OBJECTIVE This review seeks to determine if blood-based AD candidate protein biomarkers are disease specific. METHODS A two-stage systematic literature search was conducted. Firstly, the most consistently identified AD protein biomarkers in blood were determined from a list of published discovery or panel-based (>100 proteins) blood proteomics studies in AD. Secondly, an online database search was conducted using the 10 most consistently identified proteins to determine if they were involved in other brain disorders, namely frontotemporal lobe dementia, vascular dementia, Lewy body disease, Parkinson's disease, schizophrenia, depression, and autism. RESULTS Among the reviewed candidate proteins, plasma protease C1 inhibitor, pancreatic prohormone, and fibrinogen γ chain were found to have the least evidence for non-specificity to AD. All other candidates were found to be affected by other brain disorders. CONCLUSION Since we found evidence that the majority of AD candidate proteins might also be involved in other brain disorders, more research into the disease specificity of AD protein biomarkers is required.

[1]  Magda Tsolaki,et al.  Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology , 2014, Alzheimer's & Dementia.

[2]  H. Kiiveri,et al.  A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study , 2014, Molecular Psychiatry.

[3]  Charless C. Fowlkes,et al.  Feed‐forward hierarchical model of the ventral visual stream applied to functional brain image classification , 2014, Human brain mapping.

[4]  Magda Tsolaki,et al.  Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. , 2013, Journal of Alzheimer's disease : JAD.

[5]  Massimo Natale,et al.  Parkinson's disease plasma biomarkers: an automated literature analysis followed by experimental validation. , 2013, Journal of proteomics.

[6]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[7]  W. Oertel,et al.  Unimpaired postprandial pancreatic polypeptide secretion in Parkinson's disease and REM sleep behavior disorder , 2013, Movement disorders : official journal of the Movement Disorder Society.

[8]  Simone Lista,et al.  Blood and plasma-based proteomic biomarker research in Alzheimer's disease , 2013, Progress in Neurobiology.

[9]  P. Zürbig,et al.  Use of proteomic methods in the analysis of human body fluids in Alzheimer research , 2012, Electrophoresis.

[10]  R. Yolken,et al.  Identification of a blood-based biological signature in subjects with psychiatric disorders prior to clinical manifestation , 2012, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[11]  Murray Grossman,et al.  Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease , 2012, Neurology.

[12]  D. Berg,et al.  Serum and Cerebrospinal Fluid Levels of Transthyretin in Lewy Body Disorders with and without Dementia , 2012, PloS one.

[13]  Justin Bedo,et al.  Blood-based protein biomarkers for diagnosis of Alzheimer disease. , 2012, Archives of neurology.

[14]  Walter J Koroshetz,et al.  Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. , 2012, Archives of neurology.

[15]  Magda Tsolaki,et al.  Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden , 2012, PloS one.

[16]  Z. Khachaturian,et al.  Development of biomarkers to chart all Alzheimer’s disease stages: The royal road to cutting the therapeutic Gordian Knot , 2012, Alzheimer's & Dementia.

[17]  Michael D. Spain,et al.  Identification of a biological signature for schizophrenia in serum , 2012, Molecular Psychiatry.

[18]  A. de Mendonça.  Rethinking Alzheimer’s Disease , 2012, Frontiers in neurology.

[19]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[20]  P. Lewczuk,et al.  Multidimensional plasma protein separation technique for identification of potential Alzheimer’s disease plasma biomarkers: a pilot study , 2012, Journal of Neural Transmission.

[21]  C. Ahn,et al.  Lower Residual Renal Function is a Risk Factor for Depression and Impaired Health-Related Quality of Life in Korean Peritoneal Dialysis Patients , 2011, Journal of Korean medical science.

[22]  A. Hofman,et al.  Serum levels of pregnancy zone protein are elevated in presymptomatic Alzheimer's disease. , 2011, Journal of proteome research.

[23]  V. Wang,et al.  Amyloid P component as a plasma marker for Parkinson's disease identified by a proteomic approach. , 2011, Clinical biochemistry.

[24]  K. Lu,et al.  Serum IL-6, albumin and co-morbidities are closely correlated with symptoms of depression in patients on maintenance haemodialysis. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  L. Ferrucci,et al.  Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. , 2011, Journal of Alzheimer's disease : JAD.

[26]  Guanghua Xiao,et al.  A serum protein-based algorithm for the detection of Alzheimer disease. , 2010, Archives of neurology.

[27]  Susan M Resnick,et al.  Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.

[28]  Joseph V. Hajnal,et al.  A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T) , 2010, NeuroImage.

[29]  Edward T. Bullmore,et al.  Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections , 2010, PloS one.

[30]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[31]  Jun Wang,et al.  Alzheimer’s disease biomarker discovery in symptomatic and asymptomatic patients: Experimental approaches and future clinical applications , 2010, Experimental Gerontology.

[32]  A. Boyajyan,et al.  Alternative Complement Pathway in Schizophrenia , 2010, Neurochemical Research.

[33]  H. Shill,et al.  Abnormal serum concentrations of proteins in Parkinson's disease. , 2009, Biochemical and biophysical research communications.

[34]  I. Rektor,et al.  Serum inflammatory biomarkers in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[35]  A. Russo,et al.  Low Serum Alpha-1 Antitrypsin (AAT) in Family Members of Individuals with Autism Correlates with PiMZ Genotype , 2009, Biomarker insights.

[36]  P. Tariot,et al.  Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium , 2008, Neurobiology of Aging.

[37]  Eileen Daly,et al.  Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer’s disease , 2008, Journal of Neurology.

[38]  Jos H Beijnen,et al.  Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. , 2008, Current clinical pharmacology.

[39]  David R. Willé,et al.  Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium‐derived factor: Two novel biomarkers of Alzheimer's disease in human plasma , 2008, Proteomics. Clinical applications.

[40]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[41]  H. Al-Hakeim.  Serum cortisol, immunoglobulins and some complements among depressed patients , 2008, Indian Journal of Clinical Biochemistry.

[42]  B. Dean,et al.  Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder , 2008, Psychiatry Research.

[43]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[44]  K. Blennow,et al.  Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies , 2007, Neurology.

[45]  P. Liao,et al.  Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease , 2007, Proteomics. Clinical applications.

[46]  S. Lovestone,et al.  Proteome-based plasma biomarkers for Alzheimer's disease. , 2006, Brain : a journal of neurology.

[47]  Lin He,et al.  Altered levels of acute phase proteins in the plasma of patients with schizophrenia. , 2006, Analytical chemistry.

[48]  U. Adiga,et al.  otal antioxidant activity in Parkinson's Disease , 2006 .

[49]  Jan-Gowth Chang,et al.  Proteomic Identification of Lower Apolipoprotein A-I in Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.

[50]  Betül Kalender,et al.  Association of Depression with Markers of Nutrition and Inflammation in Chronic Kidney Disease and End-Stage Renal Disease , 2005, Nephron Clinical Practice.

[51]  Soo-Jung Lee,et al.  Decreased Plasma Antioxidants in Schizophrenia , 2004, Neuropsychobiology.

[52]  Deborah Pinchev,et al.  Mining biomarkers in human sera using proteomic tools , 2004, Proteomics.

[53]  H. Chertkow,et al.  Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma , 2003, Proteomics.

[54]  T. Fujita,et al.  Circulating alpha-2-macroglobulin levels and depression scores in patients who underwent abdominal cancer surgery. , 2003, The Journal of surgical research.

[55]  Matcheri Keshavan,et al.  Reduced plasma antioxidants in first-episode patients with schizophrenia , 2003, Schizophrenia Research.

[56]  Tiao-Lai Huang.  Decreased serum albumin levels in Taiwanese patients with schizophrenia , 2002, Psychiatry and clinical neurosciences.

[57]  R. W. Gracy,et al.  Identification of oxidized plasma proteins in Alzheimer's disease. , 2002, Biochemical and biophysical research communications.

[58]  T. Matsuo,et al.  Immune and hormonal activity in adults suffering from depression. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[59]  P. Mehta,et al.  Alpha2 macroglobulin elevation without an acute phase response in depressed adults with Down's syndrome: implications. , 2000, Journal of intellectual disability research : JIDR.

[60]  M. Berk,et al.  Acute phase proteins in major depression. , 1997, Journal of psychosomatic research.

[61]  J. Cummings,et al.  Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies. , 1996, Comprehensive psychiatry.

[62]  H. Neels,et al.  Total serum protein and serum protein fractions in depression: relationships to depressive symptoms and glucocorticoid activity. , 1995, Journal of affective disorders.

[63]  B. Leonard,et al.  Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. , 1994, Journal of affective disorders.

[64]  L. Minthon,et al.  Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration. , 1993, Dementia.

[65]  F. Jiménez-Jiménez,et al.  Serum levels of zinc and copper in patients with Parkinson's disease , 1992, Journal of the Neurological Sciences.

[66]  C. Swartz.  Albumin decrement in depression and cholesterol decrement in mania. , 1990, Journal of affective disorders.

[67]  Lama M Chahine,et al.  Blood-based biomarkers for Parkinson's disease. , 2014, Parkinsonism & related disorders.

[68]  Kevin J. Barnhamb,et al.  Variability in Blood-Based Amyloid-(cid:1) Assays: The Need for Consensus on Pre-Analytical Processing , 2012 .

[69]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[70]  Muzamil Saleem,et al.  Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[71]  A. Roses,et al.  The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. , 2008, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[72]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[73]  Y. Shibuya,et al.  Preliminary findings on the variation of serum apolipoprotein levels in neural degenerative disorders , 1993, Journal of clinical laboratory analysis.